Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2005-09-27
2005-09-27
Zucker, Paul A. (Department: 1621)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S291000, C514S468000
Reexamination Certificate
active
06949510
ABSTRACT:
Combinations of diterpenoid triepoxides and anti-proliferative agents are used in a combination therapy to treat hyperproliferative disorders. Anti-proliferative agents of interest include agents active in killing tumor cells, as well as immunosuppressants, and a variety of other agents that reduce cellular proliferation in targeted tissues. Synergistic combinations provide for comparable or improved therapeutic effects, while lowering adverse side effects.
REFERENCES:
patent: 5294443 (1994-03-01), Lipsky et al.
patent: 5496846 (1996-03-01), Wilson et al.
patent: 5759550 (1998-06-01), Wiedmann et al.
patent: 5843452 (1998-12-01), Wiedmann et al.
patent: 5919816 (1999-07-01), Hausheer et al.
patent: WO 95/15174 (1995-06-01), None
patent: WO 97/31921 (1997-09-01), None
patent: WO 00/48619 (2000-08-01), None
Lee et al., PG490 (Triptolide) Cooperates With Tumor Necrosis Factor-α to Induce Apoptosis in Tumor Cells, The Journal of Biol. Chem., 1999, 274(19): 13451-13455.
Gu et al. (1995), “Isolation, Purification, and Characterization of Immunosuppressive Compounds from Tripterygium: Triptolide and Tripdiolide,”Int. J. Immunopharmac., vol. 17(5):351-356.
Lee et al. (1999), “PG490 (Triptolide) Cooperates with Tumor Necrosis Factor-α to Induce Apoptosis in Tumor Cells,”Journal of Biochemistry, vol. 274(19):18451-18455.
Qiu et al. (1999), “Immunosuppressant PG490 (Triptolide) Inhibits T-cell Interleukin-2 Expression at the Level of Purine-box/Nuclear Factor of Activated T-cells and NF-κB Transcriptional Activation,”Journal of Biological Chemistry, vol. 274(19):13443-13450.
Shamon et al. (1997), “Evaluation of the Mutagenic, Cytotoxic, and Antitumor Potential of Triptolide, a Highly Oxygenated Diterpene Isolated fromTripterygium Wilfordii,” Cancer Letters, vol. 112:113-117.
Tengchaisri et al. (1998), “Antitumor Activity of Triptolide Against Cholangiocarcinoma Growth in Vitro and in Hamsters,”Cancer Letters, vol. 133:169-175.
Yang et al. (1998), “Triptolide Induces Apoptotic Death of T lymphocyte,”Immunopharmacology, vol. 40:139-149.
Lievano et al., Antitumor Effect of CPT-11, a New Derivative of Camptothecin, Against Human Prostate Cancer (PC-3) in Vitro and Prostate Rat Tumor (AT-3) in Vivo, Methods Find Exp Clin Pharmacol., 1996, 18(10): 659-62.
Wei et al., Inhibitory Effect of Triptolide on Colony Formation of Breast and Stomach Cancer Cell Lines, Cell Growth Factor Division, 1991, 12(5): 406-10.
Lennox Edwin S.
Musser John H.
Rosen Glenn D.
Bozicevic Field & Francis LLP
Pharmagenesis
Sherwood Pamela J.
The Board of Trustees of the Leland Stanford Junior University
Zucker Paul A.
LandOfFree
Uses of diterpenoid triepoxides as an anti-proliferative agent does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Uses of diterpenoid triepoxides as an anti-proliferative agent, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Uses of diterpenoid triepoxides as an anti-proliferative agent will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3401561